ScoreHaematology

MALT lymphoma prognostic index (MALT-IPI)

Estimates the risk of events in extranodal marginal zone (MALT) lymphoma using three clinical variables.

Updated 31 October 2026

When to use it

Patients with gastric or non-gastric MALT lymphoma who are candidates for systemic therapy, to stratify prognosis.

What it needs

  • Age ≥ 70 yearsYes or no
  • Ann Arbor stage III or IVYes or no
  • LDH above the upper limit of normalYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

MALT-IPI
ResultInterpretation
≤ 0Low risk: 5-year EFS ≈ 70 %
1Intermediate risk: 5-year EFS ≈ 56 %
≥ 2High risk: 5-year EFS ≈ 29 %

Practical tip

It was developed in the IELSG-19 trial (chlorambucil, rituximab or both) and validated in independent cohorts; it discriminates in both gastric and non-gastric MALT.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top